Hepatic Findings in Long-Term Clinical Trials of Ximelagatran
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 28 (4), 351-370
- https://doi.org/10.2165/00002018-200528040-00006
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementNew England Journal of Medicine, 2003
- The Epidemiology of Venous ThromboembolismCirculation, 2003
- Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety studyJournal of the American College of Cardiology, 2003
- Long-term outcomes after deep venous thrombosis of the lower extremitiesVascular Medicine, 1998
- Stroke Severity in Atrial FibrillationStroke, 1996
- Drug-Induced Hepatic DisordersDrug Safety, 1993
- Criteria of drug-induced liver disordersJournal of Hepatology, 1990